PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2023New England Journal of Medicine985 citationsOpen Access

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

BKBeate KampmannLondon School of Hygiene & Tropical MedicineSMShabir A. MadhiNational Center for Disease ControlIMIona MunjalPfizer (United States)

Key Points

Key points are not available for this paper at this time.

Abstract

RSVpreF vaccine administered during pregnancy was effective against medically attended severe RSV-associated lower respiratory tract illness in infants, and no safety concerns were identified. (Funded by Pfizer; MATISSE ClinicalTrials.gov number, NCT04424316.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kampmann et al. (2023) studied this question.

synapsesocial.com/papers/69d727ca8a0e2c5879befa97https://doi.org/10.1056/nejmoa2216480
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants2020 · 168 citations
  2. 2Detection and subgrouping of respiratory syncytial virus directly from nasopharyngeal aspirates1997 · 14 citations
  3. 3Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera2015 · 447 citations
  4. 4Challenges of Assessing Community Mortality Due to Respiratory Viruses in Children Aged Less Than 5 Years2021 · 21 citations
  5. 5Respiratory syncytial virus-associated hospitalisation in children aged ≤5 years: a scoping review of literature from 2009 to 20212022 · 38 citations